Sachs Associates’ Post

LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess. The company is working with a range of pharmaceutical license partners to develop a portfolio of CAR-IMAN cell therapies to deliver complete remission across all solid tumours before the decade is out. LIfT BioSciences was founded by Alex Blyth following the death of his mother to pancreatic cancer.  Meet LIfT BioSciences @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

Akribion Genomics develops a revolutionary, genetically-programmable and new therapy class for oncology, using novel nucleases, causing programmable cell depletion via RNA biomarker recognition. The nuclease can target a wide variety of cancer indications defined by genetic make up of patients and can also be applied beyond oncology. The nucleases are protected by a s trong IP position with FTO and the key patent granted in September 2023. The technology had initially been developed within and the company is a spin out of BRAIN Biotech, a stock listed industrial Biotech player that focuses on industrial applications. Meet Akribion Genomics AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

Fusix Biotech is an early-stage university spinout based in Munich, Germany. They are developing a completely novel, synthetic oncolytic virus platform that offers potent tumor cell killing via a unique mechanism of action, modulatory activity in the tumor microenvironment and induction of systemic anti-tumor immunity, and optimal gene delivery in an all-in-one therapeutic approach that is delivered intravenously for solid tumors. Their pipeline of """"armed"""" vectors are effective as standalone therapies or as components in combinatorial immunotherapy approaches. Fusix is currently raising a Seed financing round in order to bring its lead development candidate to IND-readiness. They are interested in meeting relevant potential investors and strategic partners. Meet Fusix Biotech GmbH @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

Alder Therapeutics is a Swedish private preclinical stage stem cell therapy development company with two promising allogeneic programs in the pipeline. Our most advanced program ALD01 is a retinal cell therapy to treat Retinitis Pigmentosa (RP), an inherited blindness disease affecting 1 in 4,000 people worldwide. Current treatments for RP are limited to one single-mutation gene therapy with few eligible patients. We have established a safe and efficacious subretinal delivery method of ALD01 cells in mice, rabbits and non-human-primate models. Following injection, ALD01 cells safely engraft and over time connect with the host retina. In a mouse retinitis pigmentosa model, we observed improved vision already 4 weeks after injection. ALD01 offers a mutation agnostic, one-time treatment option for almost all patients, thereby revolutionizing RP treatment. The estimated market opportunity is > 2,6 BUSD with peak sales 412 MUSD in 2037. Meet Alder Therapeutics AB @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

Single-Stranded Circular DNA (circDNA) in Theranostics: A Comprehensive Review A new review in Theranostics explores the exciting potential of circDNA, a type of DNA with a closed-loop structure, in the field of theranostics (therapeutics and diagnostics). With its unique properties like enhanced stability and resistance to degradation, circDNA is emerging as a valuable tool for various biomedical applications. Key Applications: Targeted Drug Delivery: circDNA aptamers, which can bind to specific targets, are being used to deliver drugs directly to cancer cells, improving their effectiveness and reducing side effects. Sensitive Bioanalysis: circDNA can be amplified using rolling circle amplification (RCA), enabling the development of highly sensitive diagnostic tests for various diseases. CRISPR-Cas9 Gene Editing: circDNA can serve as a donor template for precise gene editing using the CRISPR-Cas9 system, offering potential for treating genetic disorders. Multiscale Biomaterials: circDNA can be used to create diverse biomaterials, such as DNA origami, nanoflowers, and hydrogels, with applications in drug delivery, imaging, and tissue engineering. miRNA Inhibitors: circDNA can act as miRNA sponges, regulating gene expression and potentially suppressing tumor growth. Challenges and Future Directions: While circDNA shows great promise, challenges remain in terms of large-scale production and efficient delivery to specific tissues. However, with continued research and development, circDNA-based theranostics have the potential to revolutionize the diagnosis and treatment of various diseases. Many thanks to: Tingting Shen, Yu Zhang, Lei Mei, Xiao-Bing Zhang, and Guizhi Zhu Read the full review article here: https://lnkd.in/diV_ri6R #circDNA #Theranostics #DrugDelivery #Bioanalysis #GeneEditing #Biomaterials #miRNA #Cancer #PrecisionMedicine

Parkinson's disease drug ropinirole safely slowed the progression of ALS ✔ Amyotrophic lateral sclerosis (ALS) is progressive degeneration of motor neurons. ✔ Ropinirole hydrochloride used in treatment of Parkinson's disease identified as drug candidate during induced pluripotent stem cell (iPSC) derived motor neuron drug screening in preclinical studies ✔ Phase1/2a feasibility trial (ROPALS) evaluated safety and efficacy in ALS patients ✔ Ropinirole treated group showed safety and progression free survival of 27.9 weeks Source: Morimoto S et al. Cell Stem Cell. 2023;30(6):766-780.e9. #Amyotrophiclateralsclerosis #parkinsonsdisease #ropinirole

Exosome therapies are a new modality of ATMPs, for which no therapy has yet been commercially approved, despite several ongoing clinical trials. Exosome therapy has diverse applications:   1.    In regenerative medicine, exosomes support tissue repair in conditions like liver fibrosis and spinal cord injury. 2.    They enable targeted drug delivery by transporting therapeutic agents, such as siRNA, across the blood-brain barrier. 3.    Exosomes from mesenchymal stem cells offer immunomodulatory and anti-inflammatory effects, making them promising for cancer and gene therapy. 4.    Diagnostic use includes evaluating exosome contents in biological samples for cancer diagnosis through liquid biopsy.   At ENABLE Biotech, we have expertise and available capacity to manufacture exosome therapies as well as other advanced therapies, and our network of experts understands the unique CMC considerations for this new technology.   #exosometherapies #advancedtherapies #CMC #CDMO #biomanufacturing #biotechinnovation #ATMPs

【03/11 Taiwan Life Sciences Biweekly - Top 10 News】 🛎 [Taiwan-based] BioGate Precision Medicine Corp. held a press conference today to unveil a global milestone in innovative breakthrough in pancreatic cancer drug development. 🛎 Bora Pharmaceuticals, Onyx Healthcare , and BioLASCO 樂斯科生物科技, participate in Creative Life Science's NT$200 million cash increase. 🛎 高雄長庚紀念醫院 Discovery: Optimal model for brain stimulation therapy for bipolar disorder published in the prestigious neuroscience journal Neuroscience & Biobehavioral Reviews. 🛎 President Tsai Ing-wen and tech leaders highlighted the industry chain that has taken shape in Taiwan and artificial intelligence’s (#AI) potential in healthcare at the Institute for Biotechnology and Medicine Industry (#IBMI) annual general meeting. 🛎 Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. Receive #FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery. 🛎 Dr. Hung Wen-Chun, a distinguished researcher at the National Institute of Cancer Research of the National Health Research Institutes (#NHRI), and the collaborative research team led by Professor Chen Li-Tzong of 高雄醫學大學 reveal new target protein B-RAF, a dual precision strike against pancreatic cancer. 🛎 The #IBMI 2024 Annual General Meeting will be held on 4 March. Barry Lam, founder of the Quanta Group and vice president of IBMI, will speak at the meeting and share his views on the latest trends in the healthcare and technology industries. 🛎 浩鼎生技股份有限公司 subsidiary OBIGEN PHARMA submits Phase II clinical trial application for OBI-858 to #TFDA. 🛎 Genetic mutation patterns among glioblastoma patients in the Taiwanese population - insights from a single institution retrospective study. 🛎 Steminent Biotherapeutics, a stem cell translational medicine drug development company, plans to submit IPO application in March. Visit https://lnkd.in/gTBpFuWz for more detailed news.

🙌 Way to go for our current project, Phire! (aka ATLyphe AG) Danielle Villars, Renier Myburgh and Maddalena Marconato, together with their team, are working on an antibody-enabled blood stem cell transplantation as an intervention to cure life-threatening diseases of the blood and immune system ➡ https://lnkd.in/edbyNpgM Currently supported by Wyss Zurich, they now also gained the support from our colleagues at USZ Health Innovation Hub 😊 More info about that below 👇 #ImmuneSystem #StemCellTransplantation #InnovativeTherapies #BiotechInnovation #HealthcareAdvancements #Biotechnology #FutureOfMedicine

🫀 𝐒𝐭𝐞𝐦 𝐜𝐞𝐥𝐥𝐬 𝐟𝐨𝐫 𝐡𝐞𝐚𝐫𝐭 Understanding the genetic basis of hypertrophic cardiomyopathy (HCM), a heart disease, might help find a better treatment. The Allen Institute for Cell Science has developed pluripotent stem cell lines that contain the mutations associated with the disease, which might help develop targeted therapies. More info: https://lnkd.in/dP6KR2s9 #pharma #biotech #stemcells #randd #womeninbusiness #drjojo ---------- Hi! I am Joanna, and my friends call me Dr Jojo 🌸 𝐈 𝐭𝐚𝐥𝐤 𝐚𝐛𝐨𝐮𝐭 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐢𝐧 𝐩𝐡𝐚𝐫𝐦𝐚 𝐚𝐧𝐝 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 ♻️ Share this if you find it interesting 🔔 Follow for insights you won't want to miss